Katherine Wai

Dr. Katherine Wai


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
RLRex H. Lee
Rex H. Lee
KWKatherine Wai
Katherine Wai
JCJason W. Chan
Jason W. Chan
Patrick HaPatrick Ha
Patrick Ha
HKHyunseok Kang
Hyunseok Kang
High rates of recurrence and distant metastasis are a foremost challenge in the management of adenoid cystic carcinoma (ACC), occurring in approximately 40% of all ACC patients. Despite the morbidity and mortality resulting from recurrent/metastatic (R/M) disease, there are no FDA-approved systemic agents for these patients. In this review, we summarize pertinent ACC pathophysiology and its implications for different systemic treatment regimens in R/M ACC. We review the evidence for the most widely used systemic agents — cytotoxic chemotherapy and tyrosine kinase inhibitors (TKIs) targeting VEGFR — in addition to immune checkpoint inhibitors and non-TKI biologic agents. Exciting emerging targets for R/M ACC, including inhibitors of Notch signaling, stemness, PRMT5, and Axl, are also discussed. Lastly, we review local therapies for small-volume lung disease in patients with oligometastatic ACC, specifically pulmonary metastasectomy and stereotactic body radiation therapy (SBRT). Future development of targeted molecular agents which exploit the underlying biology of this disease may yield novel therapeutic options to improve clinical outcomes in patients with R/M ACC.

22 February 2020 in Cells
Verified
Journal Article
Open access
PDF file
KWKatherine Wai
Katherine Wai
MSMadeleine Strohl
Madeleine Strohl
AZAnnemieke van Zante
Annemieke van Zante
Patrick HaPatrick Ha
Patrick Ha
The incidence of human papillomavirus (HPV)-related head and neck squamous cell carcinoma continues to increase. Accurate diagnosis of the HPV status of a tumor is vital, as HPV+ versus HPV– tumors represent two unique biological and clinical entities with different treatment strategies. High-risk HPV subtypes encode oncoproteins E6 and E7 that disrupt cellular senescence and ultimately drive tumorigenesis. Current methods for detection of HPV take advantage of this established oncogenic pathway and detect HPV at various biological stages. This review article provides an overview of the existing technologies employed for the detection of HPV and their current or potential future role in management and prognostication.

23 October 2020 in Head & Neck
Verified
Journal Article
Open access
PDF file
KWKatherine Wai
Katherine Wai
MXMary Jue Xu
Mary Jue Xu
RLRex H. Lee
Rex H. Lee
IEIvan H. El‐Sayed
Ivan H. El‐Sayed
JGJonathan R. George
Jonathan R. George
Patrick HaPatrick Ha
Patrick Ha
Background: Guidelines regarding head and neck surgical care have evolved during the coronavirus‐19 (COVID‐19) pandemic. Data on operative management have been limited.Methods: We compared two cohorts of patients undergoing head and neck or reconstructive surgery between March 16, 2019 and April 16, 2019 (pre‐COVID‐19) and March 16, 2020 and April 16, 2020 (COVID‐19) at an academic center. Perioperative, intraoperative, and postoperative outcomes were recorded.Results: There were 63 operations during COVID‐19 and 84 operations during pre‐COVID‐19. During COVID‐19, a smaller proportion of patients had benign pathology (12% vs 20%, respectively) and underwent thyroid procedures (2% vs 23%) while a greater proportion of patients underwent microvascular reconstruction±ablation (24% vs 12%,). Operative times increased, especially among patients undergoing microvascular reconstruction±ablation (687 ± 112 vs 596 ± 91 minutes, P = .04). Complication rates and length of stay were similar.Conclusions: During COVID‐19, perioperative outcomes were similar, operative time increased, and there were no recorded transmissions to staff or patients. Continued surgical management of head and neck cancer patients can be provided safely.

16 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
RLRex H. Lee
Rex H. Lee
CECara Evans
Cara Evans
JLJoey Laus
Joey Laus
CSCristina Sanchez
Cristina Sanchez
KWKatherine Wai
Katherine Wai
Patrick HaPatrick Ha
Patrick Ha
The factors that contribute to postoperative trismus after mandibulectomy and fibula free flap reconstruction (FFFR) are undefined. We retrospectively assessed postoperative trismus (defined as a maximum interincisal opening ≤35 mm) in 106 patients undergoing mandibulectomy with FFFR, employing logistic regression to identify risk factors associated with this sequela. The surgical indication was primary ablation in 64%, salvage for recurrence in 24%, and osteonecrosis in 12%. Forty-five percent of patients had existing preoperative trismus, and 58% of patients received adjuvant radiation/chemoradiation following surgery. The overall rates of postoperative trismus were 76% in the early postoperative period (≤3 months after surgery) and 67% in the late postoperative period (>6 months after surgery). Late postoperative trismus occurred more frequently in patients with ramus-involving vs. ramus-preserving posterior mandibulotomies (82% vs. 46%, p = 0.004). A ramus-involving mandibulotomy was the only variable significantly associated with trismus >6 months postoperatively on multivariable logistic regression (OR, 7.94; 95% CI, 1.85–33.97; p = 0.005). This work demonstrates that trismus is common after mandibulectomy and FFFR, and suggests that posterior mandibulotomies that involve or remove the ramus may predispose to a higher risk of persistent postoperative trismus.

28 October 2023 in Head & Neck
Verified
Journal Article
Closed access
RLRex H. Lee
Rex H. Lee
ATAngeline Truong
Angeline Truong
XWXin Wu
Xin Wu
HKHyunseok Kang
Hyunseok Kang
AAAlain P. Algazi
Alain P. Algazi
KWKatherine Wai
Katherine Wai

14 September 2020 in Head & Neck
Verified
Journal Article
Closed access
PDF file
YCYi Cai
Yi Cai
AGArushi Gulati
Arushi Gulati
NJNicole T. Jiam
Nicole T. Jiam
KWKatherine Wai
Katherine Wai
ESElizabeth A. Shuman
Elizabeth A. Shuman
JCJolie L. Chang
Jolie L. Chang